Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Active not recruiting × olaparib × Clear all

Phase

Phase 2 53 Phase 3 15 Phase 1 13 Phase 1/2 11 Phase EARLY_PHASE1 2 Phase 4 1 Phase 2/3 1

Status

Completed 3 Unknown 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Ovarian Epithelial 1

Interventions

Human Papillomavirus Recombinant Vaccine nonavalent 5 Dexamethasone 4 Cisplatin 3 lorlatinib 2 human papillomavirus vaccine, L1 type 16, 18 2 adacel 2 Tobacco Use Cessation Devices 2 Tetanus Toxoid 2 Prednisone 2 Papillomavirus Vaccines 2 Letrozole 2 Lenalidomide 2 Diphtheria-Tetanus-acellular Pertussis Vaccines 2 Diphtheria Toxoid 2 Denosumab 2 Carboplatin 2 Cannabidiol 2 Atorvastatin 2 Anesthesia, Epidural 2 xiapex 1 venetoclax 1 trametinib 1 tirbanibulin 1 tenofovir alafenamide 1 sofosbuvir-velpatasvir drug combination 1 ruxolitinib 1 ribociclib 1 rasburicase 1 radium Ra 223 dichloride 1 pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06121401 2025-09-17

IOLANTHE

Mario Negri Institute for Pharmacological Research

Phase 4 Active not recruiting

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡